In conclusion, our results demonstrate that regulating BACE1 expression can effectively mitigate AD, highlighting the therapeutic potential of targeting the RAGE‐BACE1 pathway with RAGE modulator. The gene discussed is BACE1; the disease is Alzheimer disease.